Leys, Fabian
Eschlböck, Sabine
Campese, Nicole
Mahlknecht, Philipp
Peball, Marina
Goebel, Georg
Sidoroff, Victoria
Krismer, Florian
Granata, Roberta
Kiechl, Stefan
Poewe, Werner
Seppi, Klaus
Wenning, Gregor K.
Fanciulli, Alessandra http://orcid.org/0000-0002-2854-4179
Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
Article History
Received: 3 December 2023
Accepted: 20 March 2024
First Online: 17 April 2024
Declarations
:
: Fabian Leys: nothing to report. Sabine Eschlböck: nothing to report. Nicole Campese: nothing to report. Philipp Mahlknecht: lecture fees from AbbVie and a travel grant from Boston Scientific, outside the submitted work. Marina Peball: nothing to report. Georg Goebel: nothing to report. Victoria Sidoroff: nothing to report. Florian Krismer: personal fees from Takeda, Sanofi, Teva, Bial, and Koneksa Health in the past 12 months, and ongoing grant support paid to their institution from the Austrian Science Fund (FWF) and the National Institutes of Health, outside of the submitted work. Roberta Granata: nothing to report. Stefan Kiechl: support by VASCage, a COMET Centre within the Competence Centers for Excellent Technologies (COMET) programme funded by the Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology, the Federal Ministry of Labour and Economy, and the federal states of Tyrol, Salzburg and Vienna. COMET is managed by the Austrian Research Promotion Agency (Österreichische Forschungsförderungsgesellschaft) (FFG Project number: 898252). Werner Poewe: consultancy and lecture fees from AC Immune, Alterity, Affiris, Biogen, Lundbeck, Takeda, in relation to clinical drug development programmes for MSA. Klaus Seppi: personal fees from Ono Pharma UK Ltd, Teva, UCB Pharma, Lundbeck; grants and personal fees from AOP Orphan Pharmaceuticals AG; personal fees from Roche Pharma, Grünenthal, Stada, AbbVie, Ever Pharma, Licher Pharma, Biogen, BIAL; grants and personal fees from International Parkinson and Movement Disorders Society; grants from Michael J. Fox Foundation; grants from FWF Austrian Science Fund, outside the submitted work. Gregor K. Wenning: consultancy and lecture fees from Biohaven, Inhibicase, Lundbeck, Ono, Teva, and Theravance; research grants from the FWF Austrian Science Fund, the Austrian National Bank, the US MSA Coalition, and Parkinson Fonds Austria, outside of the submitted work. Alessandra Fanciulli: royalties from Springer Verlag; speaker fees and honoraria from Theravance Biopharma, GE Health Care, Broadview Ventures, Austrian Autonomic Society, Stopp-HSP, International Parkinson Disease and Movement Disorders Society, Elsevier; and research grants from the FWF-Austrian Science Fund, Medical University of Innsbruck, US MSA Coalition, Dr. Johannes and Hertha Tuba Foundation and Austrian Exchange Program, outside of the submitted work.
: Due to its retrospective nature and its initiation before July 2020, the present study did not require written informed consent or ethic approval. This study was notwithstanding conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments, the directives of the Austrian Agency for Research Integrity, as well as the current European Data Protection Regulation. The manuscript was prepared in line with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) Statement version 4 (see ESM).